Walleye Capital
FLGT icon

Walleye Capital’s Fulgent Genetics FLGT Stock Holding History

Walleye Capital’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-64,800
Closed -$1.46M – 4735
2025
Q3 		$1.46M Buy
+64,800
New +$1.33M 0.01% 1802
2025
Q2 		– Sell
-12,819
Closed -$217K – 4656
2025
Q1 		$217K Buy
12,819
+11,351
+773% +$193K ﹤0.01% 3211
2024
Q4 		$27.1K Buy
+1,468
New +$28.7K ﹤0.01% 4461
2024
Q3 		– Sell
-3,527
Closed -$78.9K – 5450
2024
Q2 		$69.2K Buy
3,527
+3,508
+18,463% +$73.2K ﹤0.01% 4844
2024
Q1 		$412 Sell
19
-9,501
-100% -$236K ﹤0.01% 5344
2023
Q4 		$275K Buy
+9,520
New +$255K ﹤0.01% 3436
2023
Q2 		– Sell
-25,181
Closed -$878K – 4494
2023
Q1 		$786K Buy
25,181
+1,661
+7% +$53.5K 0.01% 1341
2022
Q4 		$700K Buy
23,520
+11,389
+94% +$408K 0.01% 1219
2022
Q3 		$462K Buy
+12,131
New +$608K 0.01% 1534

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's FLGT Position: Q4 2025 in Review

Walleye Capital sold out of Fulgent Genetics (FLGT) in Q4 2025, closing a stake of 64,800 shares — an estimated $1.46M sold.

Walleye Capital first reported a position in FLGT in Q3 2022 and held it in 9 quarters. The position peaked at $1.46M in Q3 2025. 179 funds tracked by Wall St. Rank hold FLGT as of Q4 2025.

  • Walleye Capital reported no remaining Fulgent Genetics position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 64,800 Fulgent Genetics shares in Q4 2025, an estimated $1.46M.
  • Walleye Capital first reported a position in Fulgent Genetics in Q3 2022 and held it in 9 quarters.
  • Walleye Capital's Fulgent Genetics position peaked at $1.46M in Q3 2025.
  • 179 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.